Milestone Pharmaceuticals
Montreal, Quebec, Canada · Biopharma, Biotechnology, Healthcare
Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/ Milestone Pharmaceuticals Inc. (Nasdaq
Key facts
- Headquarters
- Montreal, Quebec, Canada
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (MIST)
- Website
- milestonepharma.com
- Company page
Recent activity at Milestone Pharmaceuticals
- : Milestone Pharmaceuticals names Anthony Krick Vice President, Finance
- : SEC 8-K (8.01): On September 3, 2026, Milestone Pharmaceuticals Inc. announced via press release that the National Medical Products Administration of China has approved etripamil nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. This approval represents a significant milestone for the company, enabling them to enter the Chinese market with a new therapeutic option for managing PSVT, a condition characterized by episodes of rapid heart rate. The approval may enhance the company's market presence and potentially increase revenues. The press release detailing this approval is included as Exhibit 99.1 in the filing.
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On January 26, 2026, Milestone Pharmaceuticals Inc. announced the availability of CARDAMYST (etripamil) nasal spray, which is intended for the management of paroxysmal supraventricular tachycardia (PSVT) in the United States. This announcement, made via a press release, signifies a notable development in the company's product offerings and positions CARDAMYST as a treatment option for a specific cardiac condition. The announcement included a press release attached as Exhibit 99.1, enhancing the transparency and communication regarding the product launch.
- : SEC 8-K (8.01): On January 12, 2026, Milestone Pharmaceuticals Inc. closed the sale of a royalty interest under the Royalty Purchase Agreement with RTW Royalty I DAC. This agreement, originally entered into on March 27, 2023, involved RTW purchasing the right to receive tiered quarterly royalty payments on the annual net product sales of etripamil, contingent upon FDA approval. Milestone Pharmaceuticals received a purchase price of $75.0 million from RTW for this royalty interest. This transaction marks a significant capital influx intended to support the development and commercialization of etripamil.
- : SEC 8-K (8.01): On January 6, 2026, Milestone Pharmaceuticals Inc. announced in a press release that the European Medicines Agency has accepted its Marketing Authorization Application for etripamil nasal spray. This is a significant step toward potential approval, with a decision anticipated by the first quarter of 2027. The acceptance of the application signifies a crucial development in Milestone's product pipeline, emphasizing their commitment to bringing innovative treatments to the market. The news may have important implications for investors and stakeholders regarding the future growth and viability of the company.
- : SEC 8-K (8.01): On January 6, 2026, Milestone Pharmaceuticals Inc. announced via press release that the European Medicines Agency has accepted its Marketing Authorization Application for the approval of etripamil nasal spray. The company anticipates a decision regarding this approval in the first quarter of 2027. This development is significant as it represents a crucial step towards bringing this product to market, potentially impacting the company's future financial performance and market position significantly.
- : SEC 8-K (8.01):
- : Milestone Pharmaceuticals Announces $125 Million Strategic Financing With Rtw Investments To Support The Advancement Of Etripamil For Psvt
- : Milestone Pharmaceuticals Inc.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Milestone Pharmaceuticals funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2023 | Venture | $125.0M |
| Oct 2018 | Venture | $80.0M |
| Jul 2017 | Venture | $6.9M |
| Jun 2015 | Seed | $3.8M |
Leadership
- Marco Boorsma, Director
- Nilesh Kumar, Director
- Debra Liebert, Director
- Paul Truex, Director
- Joseph Oliveto, Executive Officer, Director
- Scott Weiner, Director
- Yves Rosconi, Director
- Dion Madsen, Director
Verified email and direct lines for Milestone Pharmaceuticals’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Milestone Pharmaceuticals files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Milestone Pharmaceuticals
- Corvus Pharmaceuticals, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- vTv Therapeutics Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Praxis Precision Medicines, Inc. · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Savara Inc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Mereo Biopharma Group plc · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Milestone Pharmaceuticals: questions and answers
What does Milestone Pharmaceuticals do?
Thank you for your interest in Milestone Pharmaceuticals. While we encourage you to explore opportunities with our company, we urge you to be cautious and wary of recruitment scams in which fraudsters pose as representatives of Milestone Pharma. All current openings are available to view on our Careers page. https://milestonepharmaceuticals.applytojob.com/ Milestone Pharmaceuticals Inc. (Nasdaq
Where is Milestone Pharmaceuticals headquartered?
Milestone Pharmaceuticals is headquartered in Montreal, Quebec, Canada.
Has Milestone Pharmaceuticals raised funding?
Yes. Fundz has recorded 4 funding events for Milestone Pharmaceuticals. The most recent, $125.0M, was in Mar 2023.
What is the latest news on Milestone Pharmaceuticals?
On Nov 20, 2026, Milestone Pharmaceuticals names Anthony Krick Vice President, Finance
Is Milestone Pharmaceuticals a public company?
Yes. Milestone Pharmaceuticals is publicly traded under the ticker MIST.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy